Avian Influenza Vaccine Market By Vaccine Type (Inactivated Vaccines, live recombinant vaccines, Combination vaccines, Others), By Application (Chicken, Duck, Turkey, Goose, Others), By Strain (H5, H7, H9), By Route of Administration (Intranasal, Intramuscular, Others), and By Distribution Channel (Online, Offline {Veterinary Clinics, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Avian Influenza Vaccine market accounted for USD 0.75 Billion in 2024 and is expected to reach USD 1.53 Billion by 2035, growing at a CAGR of around 6.7% between 2025 and 2035. The Avian Influenza Vaccine Market is all about the production and marketing of vaccines to prevent avian influenza in poultry. Key players are driving the veterinary medicine market through this need to control outbreaks of bird flu and the subsequent economic losses in the poultry industry. Demand for these vaccines is also being driven by rising poultry farming, biosecurity concerns, and the zoonotic risks of the virus. Technological developments in vaccine formulations and strictly aimed regulations are key factors that influence the market. Developed as well as emerging economies from the market, seeking a solution to control this avian influenza.

Report Scope:

Market Dynamics

• Rising Global Poultry Demand Driving the Growth of the Avian Influenza Vaccine Market

Increasing poultry product demands across the world are substantial drivers for the global avian influenza vaccine market. According to the Food and Agriculture Organization (FAO), 139 million tons of poultry meat were produced in 2023, and the trend is likely to increase due to increased poultry consumption in developing economies.

There is a vulnerability on the side of poultry regarding avian influenza outbreaks in regions such as Asia and Africa, which may threaten both food security and public health. While avian production is on the rise, ensuring biosecurity measures, including widespread vaccination campaigns, is turning the attention of governments and health agencies toward protecting flocks from economic losses, resulting in increased demand for avian influenza vaccines.

• Growing Zoonotic Risk Awareness Driving Demand for Avian Influenza Vaccines

Increasing concern regarding the zoonotic risks of avian influenza has also increased demand for preventive vaccines. The World Health Organization recently informed that one particular strain of avian influenza, H5N1 and H7N9 has infected and killed humans in different parts of the world majorly where intensive poultry farming is practiced. Hence, it pushed the governments of the whole world to enhance surveillance and biosecurity measures to eliminate the possibility of transmission to humans.

For instance, China has scaled up mass vaccination programs and monitoring systems to control outbreaks of avian influenza, in recognition of the possibility that there could be cross-species transmission. The CDC in the United States also emphasizes vaccination in poultry as part of more extensive efforts to reduce the risks of zoonoses. This awareness of potential public health risks is what makes the demand for avian influenza vaccines high for preventive measures to ensure health security between animals and human beings.

• High Cost of Avian Influenza Vaccines A Barrier for Small-Scale Poultry Farmers

The high cost of avian influenza vaccines poses a significant barrier to their widespread adoption, particularly for small-scale poultry farmers. According to the Food and Agriculture Organization, poultry vaccines are not accessible to many developing country smallholder poultry farmers who lack the financial resources, with the cost running several dollars per bird depending on the region and type of vaccine.

Small-scale poultry farming is very common in a country like India and Nigeria, where the cost of vaccines easily cuts into the operational costs of farmers. This means that most small-scale farmers may forgo the vaccination process, leaving their flocks open to such instances of outbreak. To do that governments such as those in Indonesia and Egypt, have been introducing subsidy programs or selling vaccines at discounted prices to ensure that even small-scale farmers can afford them. However, this is still a huge obstacle in achieving the widest vaccination coverage and limiting avian influenza spreading.

• Affordable Vaccination Solutions for Small-Scale Poultry Farmers Driving Disease Prevention and Food Security

The program is easily characterized as a key opportunity to serve the underserved markets of small and medium-scale poultry farmers. In most developing countries smallholder poultry farmers cannot afford vaccines because of lack of capital, the recent measures undertaken by governments in countries like India, Indonesia, and Brazil recognize the necessity of providing low-cost, customized vaccination solutions.

The government has introduced subsidies and collaborated with local veterinary services to deliver low-cost vaccines for small farmers. Small-scale farmers in Africa will be the most targeted section by countries like Nigeria through high vaccination campaigns that have made vaccination relatively accessible and affordable. Through such solutions, special, low-cost vaccines might be offered to these farmers, thus increasing vaccination coverage and preventing outbreaks that may severely impact the local economy, thereby increasing food security in rural areas.

• Advancing Vaccine Development with Next-Generation Platforms for Rapid and Effective Disease Control

The use of next-generation vaccine platforms and advanced biotechnologies such as CRISPR technology represents a significant opportunity for effective and rapid responses to emergent avian influenza strains. Governments and research institutions are investing heavily in these technologies with a view to their possible contribution to enhancing vaccine development.

For instance, the USDA funded research into CRISPR-based vaccines on the acceleration of responses toward new avian influenza strains. Similarly, the European Union supports the further development of genetically engineered vaccines for efficacy improvement and reduced production times.

Next-generation platforms can potentially lead to better vaccines, more adaptable, quicker to produce, and capable of targeting multiple strains. Making it a crucial tool in better-managing outbreaks and minimizing economic and public health impacts. This approach helps more effectively control diseases worldwide, especially within extremely dynamic viral landscapes.

Industry Experts Opinion

“As agricultural and infectious disease researchers around the world continue to monitor the spread of H5N1, we continue our unwavering commitment to responding rapidly to threats to public health by providing innovative and critical tools to safeguard our global community and enable monitoring and surveillance as well as vaccine and assay development,”

• Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Segment Analysis

Based on vaccine type, the Avian Influenza Vaccine market includes inactivated, live recombinant, combination vaccines, and others. Inactivated vaccines lead due to their safety and effectiveness, making them the most widely used option in controlling outbreaks.

Based on application, the Avian Influenza Vaccine market is segmented into chicken, duck, turkey, goose, and others. Chickens lead the market due to their high population and susceptibility to avian influenza.

The Avian Influenza Vaccine market is segmented by strain into H5, H7, and H9, with H5N1 being the most targeted due to its prevalence, followed by vaccines for H7 and H9 strains to combat emerging threats. Currently, H5 vaccines lead the market due to the widespread impact of H5N1 outbreaks.

 Regional Analysis

The North American avian influenza vaccine market is the most significant in the world, supported by the large poultry industry in the United States and Canada. Recurring avian flu epidemics have increased the emphasis on a proper vaccination regimen to safeguard both the poultry industry and human health. Government efforts through stringent biosecurity measures and research funding have helped strengthen the demand for vaccines.

The U.S. market particularly has seen a tremendous rise because of the constant risk of breaks and an initiative approach to controlling diseases. Strong R&D efforts and partnerships between government agencies and private companies further increase advanced vaccines availability and thus make North America a leading region in the market.

The Asia-Pacific region is projected to be the region with the fastest growth of avian influenza vaccines due to its enormous poultry industry and repeated outbreaks of avian flu, especially in such countries as China, India, and Vietnam. High population density and the economic importance of poultry farming make this area a critical and fast-emerging market where urgent vaccinations need to be implemented, and disease management measures are significantly invested in including vaccines, by governments for livestock and human populations alike.

Advances in vaccine technology, along with increased collaboration between local governments and international vaccine manufacturers to expand market access, contribute to additional tailwinds. Growing awareness about the importance of biosecurity and increasing spending on biotechnology developments are also factors in driving growth in the market at a very rapid pace.

Competitive Landscape

The competition in the market for avian influenza vaccines is highly competitive, dominated by players such as Boehringer Ingelheim, Zoetis, Elanco, Merck & Co., Ceva Santé Animale, and Vetoquinol concerning large-scale research and product portfolio for their business. Market developments of late have been seen in the form of launches of advanced vaccine solutions by Boehringer Ingelheim and the expansion of vaccine offerings by Zoetis.

The collaboration between these companies and governments has further strengthened the distribution channel for avian flu vaccines, thereby intensifying market competition. Innovations and strategic partnerships remain key drivers in this dynamic market.

Avian Influenza Vaccine Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In November 2024, Arcturus Therapeutics announced that the U.S. FDA approved its IND application for ARCT-2304, a self-amplifying mRNA vaccine to prevent H5N1 avian influenza. Funded by BARDA, the clinical trial will involve 200 healthy adults in the U.S.
• In July 2024, Twist Bioscience launched a synthetic RNA control for H5N1 Influenza A, a cause of Highly Pathogenic Avian Influenza (HPAI). The control covers 99.9% of the hemagglutinin (HA) and neuraminidase (NA) genome regions, expanding its viral control portfolio.

Report Coverage:

By Vaccine Type

• Inactivated Vaccines
• live recombinant vaccines
• Combination vaccines
• Others

By Application

• Chicken
• Duck
• Turkey
• Goose
• Others

By Strain

• H5
• H7
• H9

By Route of Administration

• Intranasal
• Intramuscular
• Others

By Distribution Channel

• Online
• Offline
  • Veterinary Clinics
  • Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• HIPRA
• Bayer AG
• Phibro Animal Health
• Zoetis
• Ceva Santé Animale
• Merck & Co., Inc.
• Vetoquinol
• Elanco Animal Health
• Zoetis Inc.
• Boehringer Ingelheim GmbH
• Virbac
• Elanco
• Bioniche Animal Health
• Indian Immunological
• Hester Biosciences Ltd.

Frequently Asked Questions (FAQs)